PMID- 31167996
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20190819
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 60
IP  - 5
DP  - 2019
TI  - [Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole 
      during rituximab-containing chemotherapy].
PG  - 365-371
LID - 10.11406/rinketsu.60.365 [doi]
AB  - Although Pneumocystis pneumonia (PCP), a life-threatening infection, has been 
      reported in patients with non-Hodgkin B-cell lymphoma (BNHL) who were treated 
      with rituximab-containing chemotherapies (R-CTX), the PCP prophylaxis regimen 
      awaits establishment to date. This study reports a retrospective analysis of the 
      efficacy and safety of a low-dose trimethoprim/sulfamethoxazole (TMP/SMX) in 
      patients with BNHL receiving R-CTX. We retrospectively analyzed 156 patients 
      newly diagnosed with BNHL who received R-CTX at our institute from 2010 to 2015. 
      We collected patients' clinical and laboratory data, including lymphocytes count, 
      IgG level, PCP prophylaxis regimens, and adverse events (AEs). Patients were 
      categorized into the following two groups based on the TMP/SMX regimen: group A 
      (33 patients; 80 mg/400 mgx3/week) or group B (65 patients; 160 mg/800 
      mgx2/week). Both lymphocytes count and IgG level declined during R-CTX. No 
      patient developed PCP. Patients in group B exhibited a significantly higher 
      incidence of AEs (18.2% vs. 63.1%; p<0.05) and increased AST (6.1% vs. 26.6%; 
      p<0.05), compared with those in group A. Thus, TMP/SMX (80 mg/400 mgx3/week) 
      effectively prevents PCP and is preferable because of the lower rates of AEs.
FAU - Shimizu, Rie
AU  - Shimizu R
AD  - Department of Hematology and Oncology, Tosei General Hospital.
FAU - Sakemura, Reona
AU  - Sakemura R
AD  - Department of Hematology and Oncology, Tosei General Hospital.
AD  - T-Cell Engineering Program, Division of Hematology, Mayo Clinic.
FAU - Iwata, Satoshi
AU  - Iwata S
AD  - Department of Hematology and Oncology, Tosei General Hospital.
FAU - Hayakawa, Hiroshi
AU  - Hayakawa H
AD  - Department of Hematology and Oncology, Tosei General Hospital.
FAU - Miyao, Kotaro
AU  - Miyao K
AD  - Department of Hematology and Oncology, Tosei General Hospital.
FAU - Kajiguchi, Tomohiro
AU  - Kajiguchi T
AD  - Department of Hematology and Oncology, Tosei General Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*drug therapy
MH  - Pneumonia, Pneumocystis/*prevention & control
MH  - Retrospective Studies
MH  - Rituximab/*therapeutic use
MH  - Trimethoprim, Sulfamethoxazole Drug Combination/*therapeutic use
OTO - NOTNLM
OT  - B-cell lymphoma
OT  - Pneumocystis pneumonia
OT  - Rituximab
OT  - TMP/SMX
EDAT- 2019/06/07 06:00
MHDA- 2019/08/20 06:00
CRDT- 2019/06/07 06:00
PHST- 2019/06/07 06:00 [entrez]
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
AID - 10.11406/rinketsu.60.365 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2019;60(5):365-371. doi: 10.11406/rinketsu.60.365.